Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44399   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,399 result(s) found. Displaying page 2,021 of 2,220.
    «« First « Previous 2017  2018  2019  2020  2021  2022  2023  2024  2025  Next» Last»»
    EudraCT Number: 2006-005009-69 Sponsor Protocol Number: ISG STS 06 01 Start Date*: 2006-10-06
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: TRABECTEDIN (ET743) IN METASTATIC OR LOCALLY ADVANCED MYXOID/ROUND CELL LIPOSARCOMA PRETREATED WITH CHEMOTHERAPY
    Medical condition: advanced myxoid/round cell liposarcoma pretreated with anthracycline and ifosfamide
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024627 Liposarcoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000833-39 Sponsor Protocol Number: 35/04 Start Date*: 2004-10-22
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: RANDOMIZED STUDY WITH POSTOPERATIVE RADIOTHERAPY AND CONCURRENT LOW DOSE CISPLATIN VS RADIOTHERAPY AND CONCURRENT CISPLATIN + FLUOROURACIL IN OPERATED HIGH RISK SQUAMOUS CELL CARCINOMA OF T...
    Medical condition: Head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061325 Oral neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000838-21 Sponsor Protocol Number: 34/04 Start Date*: 2004-10-22
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: RANDOMIZED STUDY OF RADIOTHERAPY WITH CONCOMITANT BOOST (RTcb) AND CONCURRENT LOW DOSE CISPLATIN VS RTcb AND CISPLATIN + FLUOROURACIL IN ADVANCED HNSCC
    Medical condition: Head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10030969 Oral cavity neoplasms NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003940-61 Sponsor Protocol Number: MINT Start Date*: 2020-12-07
    Sponsor Name:Uppsala county council
    Full Title: Metformin Intervention in children and adolescents with obesity. A parallel, three arms, randomized, 6 months, multi-center study with metformin extended release (XR) plus lifestyle or metformin i...
    Medical condition: Children and Adolscents with obesity
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003616-31 Sponsor Protocol Number: 89Zirconium-ipilimumab Start Date*: 2015-12-14
    Sponsor Name:VU medical center
    Full Title: Uptake and biodistribution of 89Zirconium-labeled ipilimumab in ipilimumab treated patients with metastatic melanoma
    Medical condition: Advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001363-27 Sponsor Protocol Number: DAY101-002 Start Date*: 2023-01-18
    Sponsor Name:Day One Biopharmaceuticals, Inc. (Day One)
    Full Title: LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activati...
    Medical condition: Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) IE (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) SI (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-001605-10 Sponsor Protocol Number: INT 17/04 Start Date*: 2004-04-27
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: A Phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors GISTs resistant to imatinib mesylate
    Medical condition: Metastatic gastrointestinal stromal tumors GISTs
    Disease: Version SOC Term Classification Code Term Level
    6.1 10017992 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023135-42 Sponsor Protocol Number: VIT-0910 Start Date*: 2016-07-05
    Sponsor Name:Centre Oscar Lambret
    Full Title: INTERNATIONAL RANDOMIZED PHASE II TRIAL OF THE COMBINATION OF VINCRISTINE AND IRINOTECAN WITH OR WITHOUT TEMOZOLOMIDE (VI OR VIT) IN CHILDREN AND ADULTS WITH REFRACTORY OR RELAPSED RHABDOMYOSARCOMA
    Medical condition: Recurrent or refractory rhabdomyosarcoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039027 Rhabdomyosarcoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) NL (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001458-24 Sponsor Protocol Number: ALN-TTR02-011 Start Date*: 2019-09-19
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (...
    Medical condition: Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
    Disease: Version SOC Term Classification Code Term Level
    27.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) BG (Completed) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002909-10 Sponsor Protocol Number: P137 Start Date*: 2022-10-24
    Sponsor Name:Maastricht University
    Full Title: THE IMPACT OF PSILOCYBIN ON PAIN IN FIBROMYALGIA PATIENTS AND HEALTHY VOLUNTEERS: A MULTICENTER TRIAL
    Medical condition: Fibromyalgia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002720-91 Sponsor Protocol Number: HBnr02 Start Date*: 2017-09-21
    Sponsor Name:CyTuVax BV
    Full Title: Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders.
    Medical condition: In a minority of the population (5-10%) standard vaccines against Hepatitis-B do not induce protective immunity, even after prolonged and repeated vaccination courses. Non- responsiveness to hepati...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006040-27 Sponsor Protocol Number: CDR132L-P2-01 Start Date*: 2022-06-01
    Sponsor Name:Cardior Pharmaceuticals GmbH
    Full Title: Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction (≤ 45%) After Myocar...
    Medical condition: Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10036233 Post myocardial infarction syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000535-86 Sponsor Protocol Number: HAP.2011-002 Start Date*: 2011-03-29
    Sponsor Name:CHU AMBROISE PARE
    Full Title: A PHASE IIb STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ROPIVACAINE COMPARED TO ADRENALINE-LIDOCAINE TO REDUCE PAIN IN PATIENT UNDERGOING SURGERY FOR THIRD MOLAR TEETH EXTRACTION.
    Medical condition: third molar theeth included needing surgical extraction
    Disease: Version SOC Term Classification Code Term Level
    12.1 10044039 Tooth extraction NOS LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002332-16 Sponsor Protocol Number: RC31-16-8917 Start Date*: 2017-10-03
    Sponsor Name:Toulouse Hospital
    Full Title: Evaluation of the efficacy of injections of botulinic toxin in plantar lesions of patients suffering from localized epidermolysis bullosa simplex : double blind randomized controlled study.
    Medical condition: localized epidermolysis bullosa simplex
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001238-16 Sponsor Protocol Number: CNTO1959PSO3012 Start Date*: 2019-01-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type Psoriasis
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004942-14 Sponsor Protocol Number: IJB-LOB-2019 Start Date*: Information not available in EudraCT
    Sponsor Name:Institut Jules Bordet
    Full Title: Neoadjuvant study of targeting ROS1 in combination with endocrine therapy in invAsive Lobular carcINoma of the breast
    Medical condition: ER-positive/HER2-negative invasive lobular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073096 Invasive lobular breast carcinoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022486-10 Sponsor Protocol Number: MT-102-2001 Start Date*: 2010-11-02
    Sponsor Name:Myotec Therapeutics Limited
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subject...
    Medical condition: Cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001092-49 Sponsor Protocol Number: VPA-03 Start Date*: 2015-06-02
    Sponsor Name:Sahlgrenska Akademien Wallenberglaboratoriet
    Full Title: Valproic acid regulation of plasma PAI-1
    Medical condition: The fibrinolytic system
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10016611 Fibrinolytic activity increased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002356-27 Sponsor Protocol Number: XCGD_MOBI1 Start Date*: 2015-10-16
    Sponsor Name:Ospedale San Raffaele
    Full Title: A multicentric, exploratory, non-randomised, non-controlled, prospective, open-label phase II, study evaluating safety and efficacy of IBU, G-CSF and Plerixafor as a stem cell mobilization regimen ...
    Medical condition: X-linked chronic granulomatous disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10008906 Chronic granulomatous disease PT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004076-13 Sponsor Protocol Number: 5 Start Date*: 2006-11-28
    Sponsor Name:Huvud- hals- lung- och hudcancer, Tema Cancer Karolinska Universitetssjukhuset
    Full Title: Secar I Part I: A study of MTD of Sodium selenite in patients with advanced carcinoma. A phase I study. Amendment 5: continuous treatment
    Medical condition: Patients with stage III or IV cancer in whom first and second line treatment have been given but who have tumours that are still progressing, giving symptomes. The patients must be in a fairly good...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2017  2018  2019  2020  2021  2022  2023  2024  2025  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 12 03:13:29 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA